We are seeking a Treasurer who will be responsible for advising Trustees on all financial matters including the preparation of management and statutory accounts and to ensure the charity complies with charity law and with the requirements of the Charity Commission. We are seeking to appoint someone who has a ‘hands on’ approach whose main duties will be:
- Oversee the bookkeeping of the charity which is carried out by an external provider
- Prepare quarterly Management Accounts with variance analysis for the board
- Prepare annual accounts, for approval by trustees, and audit for the Charity Commission
- Pay all bills as signatory on the Charity bank account (subject to countersignature)
- Reclaim gift aid (quarterly)
- Oversee the Charity’s investments and bank account
- Communicate with other trustees and fund-raisers over the Charity’s financial matters.
Help with some of the above tasks could be delegated to volunteers.
As a medium-sized charity currently run exclusively by volunteers, with no paid staff, Neuroblastoma UK faces important choices over how to manage the ever-increasing demand for funding. As Treasurer you will also have the opportunity to contribute to the wider strategic development of the charity.
A head for figures and experience in financial accounting would be a good start for this position!
Just as important is an absolute desire to help us make a difference for children with neuroblastoma now and in the future by assisting us in ensuring the funds raised by our supporters are efficiently and effectively utilised in our mission to fund research for new, effective and kinder treatments.
Our charity is run entirely by volunteer effort – we have no paid staff – so the time to take a hands on approach to the job when necessary would be beneficial along with the ability to manage the volunteers who assist with the finances.
What impact the opportunity will have
Neuroblastoma UK is the leading neuroblastoma research charity in the UK, having invested over £6M in scientific research projects. Neuroblastoma is the third most common childhood cancer after leukaemia and brain tumours, but is responsible for a disproportionate number of childhood cancer deaths. Whilst survival from leukaemia has dramatically improved over recent decades due to high profile fundraising, it is now neuroblastoma that urgently needs this profile, funding and research effort. Without this research, 30-40 children will continue to die every year in the UK, with many others living with the after-effects of harsh treatments. Please consider joining us in our mission to fund new, effective and kinder treatments for children.
What’s in it for the volunteer?
Research into neuroblastoma in the UK is reliant upon charity funding. Your involvement with Neuroblastoma UK will help to ensure that the dedicated doctors, researchers and scientists around the country, who are tirelessly working to beat this disease, can continue to do so.
Either in or out of office hours
The Board typically meets up to six times a year in London or at one of the institutions throughout the UK where we currently fund research.
Communication is regularly undertaken via email and telephone between Board meetings and may take up to 2 hours per week with more time required to prepare reports prior to Board meetings and for preparation of annual accounts.
The Chair and Trustees represent Neuroblastoma UK at events local to them where possible.
The position of Honorary Treasurer is non-remunerative although reasonable expenses will be reimbursed.
About Neuroblastoma UK - registered charity no 326385
Neuroblastoma is the third most common childhood cancer but is responsible for a disproportionate number of childhood cancer deaths.
Join us at Neuroblastoma UK and help change the outlook for children with this disease.
The primary activity of the charity is fundraising and allocating funds to the best research projects through a rigorous grant assessment process. Neuroblastoma UK also organises a biennial Neuroblastoma Research Symposium, bringing the UK funding, research and clinical communities together with international experts for presentations, discussion and collaboration.